Wall Street brokerages forecast that Repligen Co. (NASDAQ:RGEN) will post $0.21 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Repligen’s earnings. The lowest EPS estimate is $0.20 and the highest is $0.22. Repligen reported earnings per share of $0.20 in the same quarter last year, which indicates a positive year-over-year growth rate of 5%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 28th.
On average, analysts expect that Repligen will report full year earnings of $0.73 per share for the current year, with EPS estimates ranging from $0.72 to $0.74. For the next financial year, analysts anticipate that the business will post earnings of $0.85 per share, with EPS estimates ranging from $0.82 to $0.92. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Repligen.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.02. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The business had revenue of $49.53 million during the quarter, compared to the consensus estimate of $46.69 million. During the same period last year, the business posted $0.15 EPS. Repligen’s revenue was up 35.4% on a year-over-year basis.
NASDAQ:RGEN traded down $0.51 during mid-day trading on Friday, hitting $54.59. The stock had a trading volume of 19,043 shares, compared to its average volume of 407,362. Repligen has a twelve month low of $29.56 and a twelve month high of $70.50. The company has a market capitalization of $2.40 billion, a P/E ratio of 79.12, a price-to-earnings-growth ratio of 3.67 and a beta of 0.96.
In other news, CFO Jon Snodgres sold 31,753 shares of the firm’s stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $63.49, for a total transaction of $2,015,997.97. Following the transaction, the chief financial officer now directly owns 32,344 shares of the company’s stock, valued at $2,053,520.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 1,763 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $65.75, for a total transaction of $115,917.25. Following the transaction, the director now directly owns 3,225 shares in the company, valued at $212,043.75. The disclosure for this sale can be found here. Insiders have sold 33,827 shares of company stock valued at $2,148,846 over the last 90 days. Company insiders own 1.40% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in RGEN. Vanguard Group Inc increased its holdings in shares of Repligen by 28.4% during the third quarter. Vanguard Group Inc now owns 3,923,135 shares of the biotechnology company’s stock worth $217,577,000 after purchasing an additional 868,093 shares during the period. Vanguard Group Inc. increased its holdings in shares of Repligen by 28.4% during the third quarter. Vanguard Group Inc. now owns 3,923,135 shares of the biotechnology company’s stock worth $217,577,000 after purchasing an additional 868,093 shares during the period. BlackRock Inc. increased its holdings in shares of Repligen by 9.1% during the second quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock worth $275,239,000 after purchasing an additional 485,777 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Repligen during the third quarter worth approximately $17,686,000. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 13.4% during the third quarter. Conestoga Capital Advisors LLC now owns 1,941,212 shares of the biotechnology company’s stock worth $107,660,000 after purchasing an additional 230,080 shares during the period. 94.35% of the stock is currently owned by institutional investors.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.